Skip to main content
AAN.com

Abstract

Objective

To investigate relationships between flortaucipir (FTP) uptake, age, and established Alzheimer disease (AD) markers in asymptomatic adults at increased risk of AD.

Methods

One-hundred nineteen individuals with a family history of AD (Presymptomatic Evaluation of Experimental or Novel Treatments of Alzheimer’s Disease [PREVENT-AD] cohort, mean age 67 ± 5 years) underwent tau-PET ([18F]FTP), β-amyloid (Aβ)-PET ([18F]NAV4694 [NAV]), and cognitive assessment. Seventy-four participants also had CSF phosphorylated tau and total tau data available. We investigated the association between age and FTP in this relatively young cohort of older adults. We also investigated regional FTP standardized uptake value ratio (SUVR) differences between Aβ-positive and Aβ-negative individuals and regional correlations between FTP and NAV retention. In cortical regions showing consistent associations across analyses, we assessed whether FTP was in addition related to CSF tau and cognitive performance. Lastly, we identified the lowest FTP value at which associations with Aβ-PET, CSF, and cognition were detectable.

Results

Increased age was associated only with amygdala and transverse temporal lobe FTP retention. Aβ-positive individuals had higher FTP SUVR values in several brain regions, further showing correlation with NAV load through the cortex. Increased FTP SUVRs in medial temporal regions were associated with increased CSF tau values and worse cognition. The SUVRs at which associations between entorhinal FTP SUVR and other AD markers were first detected differed by modality, with a detection point of 1.12 for CSF values, 1.2 for Aβ-PET, and 1.4 for cognition.

Conclusions

Relatively low FTP-PET SUVRs are associated with pathologic markers of AD in the preclinical phase of the disease. Adjustment in the tau threshold should be considered, depending on the purpose of the tau classification.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64:492–498.
2.
Ohm TG, Müller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 1995;64:209–217.
3.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–292.
4.
Ariza M, Kolb HC, Moechars D, Rombouts F, Andrés JI. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem 2015;58:4365–4382.
5.
Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 2016;80:247–258.
6.
Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegener 2017;12:19.
7.
Schöll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron 2016;89:971–982.
8.
Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 2016;139:1539–1550.
9.
Lowe VJ, Wiste HJ, Senjem ML, et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain 2018;141:271–287.
10.
Mishra S, Gordon BA, Su Y, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage 2017;161:171–178.
11.
Cannon-Albright LA, Foster NL, Schliep K, et al. Relative risk for Alzheimer disease based on complete family history. Neurology 2019;92:e1745–e1753.
12.
Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 Census. Neurology 2013;80:1778–1783.
13.
Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM. Rationale and structure for a new center for studies on prevention of Alzheimer's disease (STOP-AD). J Prev Alzheimers Dis 2016;3:36–42.
14.
Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage 2010;53:1181–1196.
15.
Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–980.
16.
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015;138:2020–2033.
17.
Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310–1323.
18.
Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. Data Brief 2017;15:648–657.
19.
Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Demen 2018;10:232–236.
20.
Marquié M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787–800.
21.
Villeneuve S, Vogel JW, Gonneaud J, et al. Proximity to parental symptom onset and amyloid-β burden in sporadic Alzheimer disease. JAMA Neurol 2018;75:608–619.
22.
Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310–319.
23.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 1995;57:289–300.
24.
Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage 2014;92:381–397.
25.
Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755–766.
26.
Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 2018;320:1151–1162.
27.
Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960–969.
28.
Kaufman SK, Del Tredici K, Thomas TL, Braak H, Diamond MI. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART. Acta Neuropathol 2018;136:57–67.
29.
Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804.
30.
Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage 2017;157:448–463.
31.
Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement 2017;13:205–216.
32.
Mormino EC, Brandel MG, Madison CM, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012;59:1152–1160.
33.
Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning: long way ahead. Neurology 2019;93:72–79.
34.
Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 2016;4:58.
35.
Smith R, Wibom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol 2019;76:310–317.
36.
Marquié M, Siao Tick Chong M, Antón-Fernández A, et al. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol 2017;134:619–628.
37.
Schöll M, Ossenkoppele R, Strandberg O, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain 2017;140:2286–2294.
38.
Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–128.
39.
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–144.
40.
Barthélemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease. Front Aging Neurosci 2019;11:121.
41.
La Joie R, Bejanin A, Fagan AM, et al. Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 2018;90:e282–e290.
42.
Mattsson N, Schöll M, Strandberg O, et al. 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. EMBO Mol Med 2017;9:1212–1223.
43.
Chhatwal JP, Schultz AP, Marshall GA, et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 2016;87:920–926.
44.
Gordon BA, Friedrichsen K, Brier M, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain 2016;139:2249–2260.
45.
Vemuri P, Lowe VJ, Knopman DS, et al. Tau-PET uptake: regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement (Amst) 2016;6:21–30.
46.
Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci 2018;38:4482–4489.

Information & Authors

Information

Published In

Neurology®
Volume 94Number 11March 17, 2020
Pages: e1190-e1200
PubMed: 32015176

Publication History

Received: March 22, 2019
Accepted: September 27, 2019
Published online: February 3, 2020
Published in print: March 17, 2020

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

This study was funded by the Alzheimer Society of Canada and Brain Canada (NIG-17-08), the Quebec Bio-Imaging Network (M.M.), Healthy Brains, Healthy Lives (M.M.), the Alzheimer's Association (NIRG-397028), McGill University (J.B., J.P.), the Fonds de Recherche du Québec–Santé (J.B., J.P.), an unrestricted research grant from Pfizer Canada (J.B., J.P.), the Levesque Foundation (J.P.), the Douglas Hospital Research Centre and Foundation (J.B., J.P.), the Canada Institutes of Health Research (PJT-162091 and PJT-148963), and the Canada Fund for Innovation (S.V.).

Authors

Affiliations & Disclosures

Melissa McSweeney, MSc*
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alexa Pichet Binette, MSc*
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pierre-François Meyer, PhD
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
P.-F.M. is supported by funding from the Canada First Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives initiative and by the Lazlo & Etelka Kollar fellowship fund for this project.
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Julie Gonneaud, PhD
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Christophe Bedetti, MSc
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Hazal Ozlen, BSc
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anne Labonté, BSc
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Pedro Rosa-Neto, MD, PhD https://orcid.org/0000-0001-9116-1376
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
(1) Enigma radiopharmaceutical (2) Kalgene
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
associate editor: Frontier in Aging Neurosciences
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Enigma pharmaceuticals (2) Eli-Lilly
Research Support, Government Entities:
1.
(1) FRSQ, 35271, principal applicant, 2014-2018 (2) CIHR, 363444, co-applicant, 2016-2019 (3) CIHR, 366009, co-applicant, 2016-2020 (4) CIHR, 201312CNA-322265-CNA-CFAF-32054, co- investigator, 2014-2019
Research Support, Academic Entities:
1.
(1) Merck, Sharpe & Dohme Corporation/McGill Faculty of Medicine Grant for Translational Research
Research Support, Foundations and Societies:
1.
(1) Weston Brain Institute (2) Alzheimer's Association (3) Brain Canada CQDM
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
John Breitner, MD, MPH
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
(1) Mayo Clinic Studies on Aging, Scientific Advisory Board (NIH-funded program) (2) Data and Safety Monitoring Board, SPRINT-MIND clinical trial (NIA / NHLBI sponsor) (3) Consultant to Cerespir Pharmaceuticals
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Receive occasional honoraria for industry-sponsored talks
Editorial Boards:
1.
Alzheimer's Disease and Associated Disorders, Editorial Board, 2003 - present; PLOS-One, Academics, 2009 - present; Alzheimer's and Dementia, Editorial Board, 2007 - present;
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Research Support (gift) from Pfizer Canada
Research Support, Government Entities:
1.
(1) Fonds de Recherche du Quebec - Sante PI 2012-2015 CIHR 2019-
Research Support, Academic Entities:
1.
(1) Program support from McGill University Faculty of Medicine
Research Support, Foundations and Societies:
1.
(2) Research support from the Douglas Hospital Research Centre and the Douglas Hospital Foundation.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Judes Poirier, PhD
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
1) Fondation Alzheimer (France)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease, Associate Editor, 2017- 2019
Patents:
1.
NONE
Publishing Royalties:
1.
Young and Centanarian, Trécarré (Canada), 2017 Alzheimer's Disease: The Complete Guide, 2012
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
J.L. Levesque Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sylvia Villeneuve, PhD
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Canadian Institutes of Health Research, post-doctoral fellowship, 02/12 to 01/15
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
for the PREVENT-AD Research Group
From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.

Notes

Correspondence Dr. Villeneuve [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
*
These authors contributed equally to this work.
PREVENT-AD Research Group coinvestigators are listed in Appendix 2 at the end of the article.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies, Drug Research, (2023).https://doi.org/10.1055/a-2181-0813
    Crossref
  2. A bioinspired fluorescent probe based on metal–organic frameworks to selectively enrich and detect amyloid-β peptide, Chemical Engineering Journal, 470, (144124), (2023).https://doi.org/10.1016/j.cej.2023.144124
    Crossref
  3. Trait Mindfulness Is Associated With Less Amyloid, Tau, and Cognitive Decline in Individuals at Risk for Alzheimer’s Disease, Biological Psychiatry Global Open Science, 3, 1, (130-138), (2023).https://doi.org/10.1016/j.bpsgos.2022.01.001
    Crossref
  4. Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults , Annals of Neurology, 91, 4, (548-560), (2022).https://doi.org/10.1002/ana.26308
    Crossref
  5. Characterization of the contactin 5 protein and its risk‐associated polymorphic variant throughout the Alzheimer's disease spectrum, Alzheimer's & Dementia, 19, 7, (2816-2830), (2022).https://doi.org/10.1002/alz.12868
    Crossref
  6. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition, JAMA Neurology, 79, 10, (1025), (2022).https://doi.org/10.1001/jamaneurol.2022.2442
    Crossref
  7. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment, JAMA Neurology, 79, 10, (975), (2022).https://doi.org/10.1001/jamaneurol.2022.2379
    Crossref
  8. Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease, eLife, 10, (2021).https://doi.org/10.7554/eLife.62929
    Crossref
  9. Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum, Genes, 12, 11, (1805), (2021).https://doi.org/10.3390/genes12111805
    Crossref
  10. Relationships Between Cognition and Neuropathological Tau in Alzheimer’s Disease Assessed by 18F Flortaucipir PET, Journal of Alzheimer's Disease, 80, 3, (1091-1104), (2021).https://doi.org/10.3233/JAD-200808
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share